This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Biotech Stock Roundup: AGEN, SRPT Surge & BIIB, REGN Provide Pipeline Updates
by Zacks Equity Research
The biotech sector was in focus last week with pipeline and regulatory updates from Agenus (AGEN) and Sarepta (SRPT), among others.
Biogen (BIIB) Eye Disease Drug Misses Primary Goal in Study
by Zacks Equity Research
Biogen's (BIIB) rare, inherited retinal disease candidate, cotoretigene toliparvovec fails to meet the primary endpoint in a phase II/III study.
Biogen (BIIB) Decides to Acquire Phase II Stroke Candidate
by Zacks Equity Research
Biogen's (BIIB) decision to acquire TMS-007 is based on positive data from a phase IIa study, which met its primary safety objective with no incidence of symptomatic intracranial hemorrhage (sICH)
The Zacks Analyst Blog Highlights: Regeneron, Moderna, Minerva Neurosciences, Amgen and Biogen
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Regeneron, Moderna, Minerva Neurosciences, Amgen and Biogen
Biotech Stock Roundup: REGN's Q1 Earnings Update, MRNA's Vaccine Data & More
by Zacks Equity Research
The biotech sector was in focus last week with earnings updates from Regeneron (REGN) and Moderna (MRNA) and regulatory updates from Amgen, among others.
Biogen (BIIB) Signs New Gene Therapy Deal for CNS Disorders
by Zacks Equity Research
Biogen (BIIB) and Capsigen set to collaborate to make AAV capsids that have the potential to deliver transformative gene therapies for various CNS and neuromuscular disorders.
How Will Biotech ETFs React to These Q1 Earnings Releases?
by Sweta Jaiswal, FRM
Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.
Ionis (IONS) Q1 Loss Widens Year Over Year, Sales Miss
by Zacks Equity Research
Ionis (IONS) Q1 adjusted loss per share was wider than the year-ago figure. The company maintains its guidance for 2021.
Denali's (DNLI) Q1 Earnings Miss Estimates, Revenues Up Y/Y
by Zacks Equity Research
Denali (DNLI) posts a wider-than-expected loss in the first quarter of 2021 due to higher R&D costs.
Biotech Stock Roundup: BIIB, AMGN's Q1 Earnings Updates & Other Pipeline News
by Zacks Equity Research
The biotech sector was in focus last week with earnings updates form Biogen (BIIB) and Amgen (AMGN), and regulatory updates from Bristol Myers (BMY), among others.
Pharma/Biotech Stocks' Q1 Earnings Queued for Apr 29: MRK, BMY & More
by Zacks Equity Research
Let us take a look at what is in store for some of the pharma/biotech stocks, which are scheduled to report on Apr 29.
Alzheimer's Disease: 5 Stocks on Biotech Radars
by Kevin Cook
While Biogen rides a big-cap rollercoaster, a few small players are creating better trading opps.
Biogen (BIIB) Q1 Earnings Top, Sales Down as Key Drugs Falter
by Zacks Equity Research
Biogen (BIIB) beats first-quarter estimates for both earnings and sales and ups earnings guidance for 2021.
Biogen Inc. (BIIB) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Biogen Inc. (BIIB) delivered earnings and revenue surprises of 5.53% and 0.39%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Biogen (BIIB) to Report Q1 Earnings: Will It Beat Estimates?
by Zacks Equity Research
Investor focus is likely to be on sales numbers of Tecfidera and Spinraza when Biogen (BIIB) reports first-quarter earnings.
Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Biogen Inc. (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: GILD's UC Drug Approval, REGN's COVID-19 Antibody Data & More
by Zacks Equity Research
The biotech sector was in focus last week with regulatory updates from Gilead (GILD) and COVID-19 study updates from Regeneron (REGN), among others.
Sage (SAGE), Biogen Report Positive Data on Essential Tremor Study
by Zacks Equity Research
Sage (SAGE) and partner Biogen (BIIB) announce positive top-line results from the phase II, placebo-controlled KINETIC study in patients with essential tremor.
AbbVie (ABBV) Seeks Skyrizi Approval for Psoriatic Arthritis
by Zacks Equity Research
AbbVie (ABBV) files regulatory applications with the FDA and the EMA, seeking approval for a new indication of Skyrizi - psoriatic arthritis.
AbbVie's (ABBV) Rinvoq Dermatitis sNDA Review Gets Delayed
by Zacks Equity Research
The FDA extends the review period of AbbVie's (ABBV) label expansion application for Rinvoq in atopic dermatitis by three months.
Roche's (RHHBY) SMA Treatment Evrysdi Secures EC Approval
by Zacks Equity Research
Roche (RHHBY) gains a regulatory nod for its SMA treatment Evrysdi in Europe for patients aged two months and above.
Novartis (NVS) Gets EC Nod For Kesimpta in Relapsing Forms of MS
by Zacks Equity Research
The European Commission approves Novartis' (NVS) Kesimpta for the treatment of adult patients with relapsing forms of multiple sclerosis.
Ionis (IONS) Crashes as Roche-Partnered Huntington's Drug Fails
by Zacks Equity Research
Ionis (IONS) stock sinks as partner Roche stops dosing in a late-stage study on tominersen in Huntington's disease.
AbbVie (ABBV) Down as FDA Extends Review of Rinvoq sNDA
by Zacks Equity Research
The FDA extends the review period of AbbVie's (ABBV) label expansion application for Rinvoq in active psoriatic arthritis by three months.
Lilly (LLY) Down as Alzheimer's Drug Fails Investor Expectation
by Zacks Equity Research
Eli Lilly (LLY) announces detailed data on secondary endpoints of its mid-stage study evaluating its antibody candidate, donanemab, in patients with early symptomatic Alzheimer's disease.